CollPlant Biotechnologies Ltd

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company specializing in medical aesthetics and 3D bioprinting of tissues and organs. The company's products are built on its recombinant human collagen (rhCollagen), which is produced in genetically engineered tobacco plants using proprietary technology. These products are designed for various applications in tissue repair and aesthetics. In February 2021, CollPlant Biotechnologies Ltd entered into the AbbVie Development Agreement with Allergan, an AbbVie company. Under this agreement, AbbVie is developing dermal and soft tissue filler products for the medical aesthetics market, combining CollPlant's rhCollagen technology with AbbVie's technology. In February 2025, CollPlant Biotechnologies Ltd announced a development milestone for this product candidate, triggering a $2 million payment from AbbVie. This followed a previous achievement announced in June 2023, which resulted in a $10 million payment from AbbVie. The dermal filler product candidate is currently in the clinical phase, with AbbVie reviewing interim results from the first patient cohort from trials initiated in 2023. AbbVie is responsible for designing, planning, and executing these trials and will determine the program's next steps after its assessment. CollPlant Biotechnologies Ltd also develops its own medical aesthetics products, including a Photocurable Dermal Filler and 3D-bioprinted Breast Implants. The photocurable regenerative dermal filler combines rhCollagen and other biomaterials, designed for skin lifting, rejuvenation, and facial contouring. In September 2025, the company announced positive non-clinical results for this photocurable dermal filler and plans to advance it into clinical trials. In February 2026, CollPlant Biotechnologies Ltd announced the strategic positioning of its photocurable dermal filler platform to address facial volume loss, including in patients undergoing GLP-1 therapies.